Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “MEDROXYPROGESTERONE”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 1,261 records · Page 70Linked to original sources
PubMed1990

[A case of marked effectiveness using medroxyprogesterone acetate (MPA) in lung metastases of cancer of the uterine body].

This case is a 71-year-old female. As hormonotherapy, 400 mg/day of MPA alone was orally administered in a lung metastatic case of cancer of the uterine body in the IV stage. Although progressing for 2 years and 1 month after the initial administration, lung metastatic foci disappeared, and recurrence was not noted, and serious side effect by using MPA was also not noted. Progesterone therapy such this case is considered as one of therapeutic methods which can be expected remarkably effective rate in the lu metastatic foci of cancer of the uterine body.

Administration, Oral↗
PubMed1986

Protective effect of high-dose medroxyprogesterone acetate (HD-MPA) on hematological toxicity induced by chemotherapy for advanced solid tumors: a multicentric controlled clinical trial. MPA-Hematology Italian Cooperative Group.

A multicenter, randomized, controlled trial was conducted comparing active treatment with placebo in 227 patients with breast, colorectal, lung and other solid forms of cancer. Combination therapy, (CT) conventionally employed for the various types of tumor involved, was associated with MPA (117 patients) or placebo (110 patients). MPA was given orally as tablets, as a dose of 500 mg b.i.d. for 6 months. The results were, briefly, as follows: The incidence of leukopenia was significantly lower in the groups receiving MPA in patients with breast and colorectal cancer (P less than 0.02). Tumors of the lung and other solid forms showed no such difference. The incidence of thrombocytopenia was the same in all disease groups. Objective responses (CR + PR) were observed in 23/46 (50%) of breast cancer patients treated with CT + MPA, and in 13/47 (28%) of those given CT + placebo. The difference was significant (P less than 0.02). Subjective parameters also showed more improvement in the MPA group than in the patients given CT alone. No significant differences were found for the other types of tumor, but the numbers in this population were very limited. In a group of 45 patients, antithrombin III a (%), antithrombin III R: Ag (%), plasminogen (mg/dl), alpha-2 macroglobulin (%), factor VIII C (%), factor VIII R: Ag (%) and factor IX C (%) were determined. The most interesting post-treatment findings were an increase in anti-thrombin III (activity and antigen level) and in plasminogen. This suggests that MPA does not increase the risk of thrombosis, and might even, to some extent, impede tumor-induced thrombophilia.(ABSTRACT TRUNCATED AT 250 WORDS)

Adult↗
PubMed1985

Analgesic activity of medroxyprogesterone acetate (MAP) in cancer patients: an antiinflammatory mediated activity?

When we initially used high doses of MAP (greater than 500 mg/day/im or greater than 2000 mg/day p.o.) in advanced cases of breast cancer, we noticed that, even before objective remission became apparent, the treatment induced subjective remission and a strong analgesic effect. Overall, our breast cancer patients treated with MAP at high doses (300 patients) showed a 65% incidence of pain relief. The analgesic effect of MAP does not seem to be closely related to its antitumour effect, because the same effect was also observed in patients with hormone-insensitive tumours. Our pharmacokinetic studies have demonstrated that it is important to use high doses in order to obtain high plasma levels. In order to clarify the mode of action of this MAP analgesy, hot-plate, tail-flick, Randall, writhing and carrageenin-oedema tests were carried out on rats. We found no evidence for central or peripheral analgesic activity, but there was evidence for an antiinflammatory activity of MAP.

Animals↗
PubMed1986

[Combined therapies with medroxyprogesterone acetate (MPA) in DMBA-induced rat mammary cancer].

Sixty-one female SD rats with 7, 12-dimethylbenz(a) anthracene (DMBA)-induced mammary cancer were divided into six groups according to the antitumor agent administered: MPA (20 mg/kg, Im), FT 207 (40 mg/kg, Ip), MPA (20 mg/kg, Im) + FT 207 (40 mg/kg, Ip), E2 priming (3 micrograms/body, Im, three days) + MPA (20 mg/kg, Im), E2 (3 mg/body, Im, three days) + MPA (20 mg/kg, Im) and control. The sizes of the tumors in all DMBA rats were measured at 1, 2, 3 and 4 weeks after the start of the administration, and the antitumor effects were compared among the groups. The antitumor effect of MPA + FT 207 was better than that when they were administered separately. It was shown that chemo-endocrine therapy with MPA was very effective. The antitumor effect was in the order of E2 priming + MPA, E2 + MPA and MPA among these three groups. E2 priming before MPA administration was thought to be very promising. The progesterone receptor (PgR) level tended to increase by E2 priming in DMBA tumors. Furthermore, in the E2 priming + MPA group, the tumors with high PgR levels before therapy tended to be more responsive than those with low PgR levels.

9,10-Dimethyl-1,2-benzanthracene↗
PubMedDate not supplied

Oral versus intramuscular high-dose medroxyprogesterone acetate (HD-MPA) in advanced breast cancer. A randomized study of the Belgian Society of Medical Oncology.

Ninety postmenopausal women with advanced breast cancer were randomly assigned to be treated with HD-MPA administered either by oral route (daily dose 900 mg) or by intramuscular injections (1 g IM daily X 5 q w during 4 consecutive weeks followed by maintenance with 1 g twice weekly). Among 78 evaluable cases, most heavily pretreated, remissions, lasting for a median duration of 11 months, were more frequent on oral (8/37 = 22%) than on IM therapy (5/41 = 12%). In both arms, high estrogen receptor levels and various clinical factors were associated with higher response rates i.e., age greater than 60, Karnofsky greater than 70, light prior systemic treatment. Side-effects, consisting mainly of weight gain, hypertension and tremor occurred with equal frequency on oral or IM treatment. Five patients complained of pain at the sites of IM injections. Thus, we recommended that, whenever possible, the oral route should be preferred. During the same study, in 20 patients (11 on oral and 9 on IM therapy), blood was drawn at 0, 30, and 60 days of treatment for the assessment of MPA and hormone levels. In both arms, at 60 days, comparable levels of circulating MPA were obtained, with a very significant drop of cortisol, androstenedione, and estrone. These endocrine results, together with our clinical data, indicate that HD-MPA therapy is active on estrogen-dependent tumors with the same specificity as that of other modalities aiming to suppress the adrenal function. Its antineoplastic action in humans could be ascribed at least in part to its suppressive action on the adrenals, resulting in a severe estrogenic deprivation in postmenopausal women.

Administration, Oral↗
PubMedDate not supplied

Improvement of hematological and general tolerance to CMF by high-dose medroxyprogesterone acetate (HD-MPA) adjuvant treatment for primary node positive breast cancer (analysis of 100 patients).

In a prospective randomized trial comparing CMF to CMF + HD-MPA for primary node positive breast cancer patients, the authors evidenced clear improvement of hematological tolerance (especially of WBC - granulocytes counts) to chemotherapy in the group receiving also hormonotherapy. The design of the trial allowed to give the patients overall high doses of CMF therapy in both arms; in the group receiving HD-MPA significantly higher doses of CMF could be administered (96.3-97.8% for CMF + HD-MPA treated patients vs 89.7-91.1% for CMF alone treated patients). The menopausal status did not influence the results.

Adult↗